Categories Earnings, Health Care

Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot

— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.   

— Total operating expenses were $3.2 million.

— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.

— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.  

— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.  

— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.  

— ACHV shares were up 12.7% in premarket hours on Friday.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Stitch Fix (SFIX) Stock: Will the innovative biz model survive virus-led slump?

The business world is still struggling to come out of the virus-induced slowdown, but it seems almost every retail segment benefited from the pandemic at some point. The vaccination drive

General Mills (GIS): Three factors that are expected to help drive growth for the food company going forward

Shares of General Mills Inc. (NYSE: GIS) were up 3.2% on Wednesday after the company delivered better-than-expected results for the first quarter of 2022. Net sales rose 4% year-over-year to

IPO Alert: Allvue Systems sets IPO terms, to raise around $290 million

It is estimated that the alternative investments industry has expanded at a compound annual rate of 10.2% over the past ten years and had $11 trillion in assets under management

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top